NRX PharmaceuticalsNRXP
About: NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
10,000% more call options, than puts
Call options by funds: $202K | Put options by funds: $2K
0.68% more ownership
Funds ownership: 4.09% [Q1] → 4.77% (+0.68%) [Q2]
29% less capital invested
Capital invested by funds: $1.78M [Q1] → $1.26M (-$521K) [Q2]
42% less funds holding
Funds holding: 31 [Q1] → 18 (-13) [Q2]
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
93% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 14
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Ascendiant Capital Edward Woo 29% 1-year accuracy 10 / 34 met price target | 3,420%upside $44 | Buy Maintained | 12 Sept 2024 |
HC Wainwright & Co. Vernon Bernardino 50% 1-year accuracy 7 / 14 met price target | 1,420%upside $19 | Buy Maintained | 5 Aug 2024 |